semaglutide trial adolescents obesity 2022 GLP-1 Agonists in Adolescent Obesity: A Review of Single, Dual, and Tr | DMSO 50 mg of oral #semaglutide

Physicians and pharmacies can continue to prescribe and compound GLP-1 medications under specific circumstances

From a technical standpoint, this raises a question about the boundary between legitimate pharmacy customization and marketing-driven personalization. The researchers note that while compounding can sometimes be clinically justified, many added ingredients have limited evidence for improving safety, efficacy, or metabolic outcomes in the context of GLP-1 therapy

Still, experts caution that combination therapy may not be appropriate for everyone and should be discussed with a doctor or other medical professional

At Scripta, we're here to break down those barriers and help plan members understand their options while reducing the confusion, stress and the guesswork that is standing in the way of better health." The GLP-1 Navigator is part of Scripta's larger Rx Navigation platform, a tailored solution for plan sponsors to better manage skyrocketing pharmacy benefit costs, while helping their members get The Right Meds at The Best Price